BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Northeastern University researchers resurrected an extinct plant gene, turning back the evolutionary clock to pave a path forward for the development and discovery of new drugs.

Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...

After an earlier trial showed patients with elevated levels of a cardiac stress marker benefited from its cell therapy, the firm shifted focus to this subset.

The trial is assessing the therapy for individuals with ischemic heart failure of minimised ejection fraction.

Fire1 announced positive results from the first-in-human study of its novel, implantable heart failure (HF) management system ...

Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.